Do Texas' Politicians Hate Texans?

By Henry I. Miller, MS, MD — Jan 23, 2024
Reflecting their baseless antagonism towards COVID vaccines, the state's legislature, governor, and attorney general have made decisions that will have deadly consequences for many Texans.

Texas’ political leaders recently have made some inconceivably irresponsible policy decisions. One will cause real public health damage to Texans, while the other simply reflects ignorance and will waste the state’s resources on a frivolous lawsuit.

In November, Texas Governor Greg Abbott signed legislation that imposes a sweeping ban on COVID-19 vaccine mandates for all private businesses. It provides no exceptions for doctors' offices, clinics, or other health facilities and has been described as "the latest blow to medically vulnerable Texans who rely on others' immunization to shield themselves from highly transmissible viruses." Cancer patients are especially vulnerable to infectious diseases, and in 2022, Texas' M.D. Anderson Cancer Network alone had 175,719 patients, who accounted for 1.6 million outpatient visits.

Texas has the sixth lowest rate of COVID boosters in the country, which makes it particularly unthinkable that M.D. Anderson and other healthcare institutions can no longer require that their employees be vaccinated to prevent them and their patients from contracting an infection that often has significant sequelae (long COVID) and is potentially lethal.

Also in November, Texas Attorney General Ken Paxton filed a lawsuit accusing pharmaceutical company Pfizer of “unlawfully” and “intentionally” misrepresenting the effectiveness of its Covid-19 vaccine and attempting to censor its critics. The suit alleges that the company “engaged in false, deceptive, and misleading acts and practices by making unsupported claims regarding the company’s COVID-19 vaccine in violation of the Texas Deceptive Trade Practices Act.”

The pivotal allegation is that “[t]he pharmaceutical company's widespread representation that its vaccine possessed 95% efficacy against infection was highly misleading.” The suit also accuses Pfizer of conducting a “scheme of serial misrepresentations” and seeks $10 million in reparations.

Attorney General Paxton and his staff must have spent too much time listening to pundits on Fox News Channel and too little time performing due diligence. Contrary to much of the blather from anti-vaccine, COVID-minimizing armchair experts, the first round of COVID vaccines – which were developed and tested with the help of the federal government’s Operation Warp Speed – did prevent infection. That was evident from the summary of Pfizer’s clinical trial data presented by the FDA to its vaccines advisory committee in December 2020.

In the pivotal clinical trial, which included more than 44,000 subjects, the two criteria for efficacy (pages 13-14) were the prevention of (1) a positive virological test plus (2) at least one COVID-19 symptom. If the vaccine met those criteria, it would be considered to be efficacious at preventing infection. The FDA’s “Efficacy Summary” (page 32) concludes:

The data submitted in this EUA [Emergency Use Authorization] request were consistent with the recommendations set forth in the FDA Guidance on Emergency Use Authorization for Vaccines to Prevent COVID-19 and met the prespecified success criteria established in the protocol. In the planned interim and final analyses, vaccine efficacy after 7 days post Dose 2 was 95%, (95% CI 90.3; 97.6) in participants without prior evidence of SARS-CoV-2 infection and >94% in the group of participants with or without prior infection. (Emphasis added.)

Numerous studies from academia, some of which were summarized by Yale Medicine, confirm the efficacy of the original vaccines and the subsequent boosters. An analysis by The Commonwealth Fund, a nonprofit that conducts independent healthcare research, estimated that COVID-19 vaccination in the U.S. prevented more than 3 million additional deaths, 18.5 million additional hospitalizations, and 120 million more cases from December 2020 through November 2022.  

See you in court, Mr. Attorney General.

It may not be strictly pertinent to the lawsuit, but it is instructive to compare the high level of efficacy of the Pfizer COVID vaccine to the usual efficacy of seasonal flu vaccines, which are in the range of 40-60% in preventing infection.

What is pertinent to the lawsuit is that after the initial testing and distribution of the Pfizer vaccine under an Emergency Use Authorization granted by the FDA, the SARS-CoV-2 virus evolved in unanticipated but significant ways. New variants have become more transmissible and more capable of immune escape – that is, less susceptible to the immunity conferred by previous infection or vaccination. That means that the COVID vaccines are less able to prevent infection, but -- this is important – they continue to be very effective against severe infection, hospitalization, and death.

Another important point is that the value of COVID vaccines is further bolstered by real-world data on one of COVID’s most significant burdens – long COVID, the persistence of various signs or symptoms and damage to organs for months or even years following the acute infection. A Swedish study involving more than half a million adults found a 58% lower risk of post-COVID conditions in individuals vaccinated with “available vaccines,” which included the Pfizer vaccine and four others. Notably, a dose-response relationship showed escalating protection against long COVID with subsequent vaccine doses.

It is unfortunate that Texas’ legislature and executive branch harbor baseless antagonism towards one of the most important preventive-medicine advances of this century. By lessening vaccine uptake, their policies will have deadly consequences.

Category

Henry I. Miller, MS, MD

Henry I. Miller, MS, MD, is the Glenn Swogger Distinguished Fellow at the American Council on Science and Health. His research focuses on public policy toward science, technology, and medicine, encompassing a number of areas, including pharmaceutical development, genetic engineering, models for regulatory reform, precision medicine, and the emergence of new viral diseases. Dr. Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts, including as the founding director of the Office of Biotechnology.

Recent articles by this author:
ACSH relies on donors like you. If you enjoy our work, please contribute.

Make your tax-deductible gift today!

 

 

Popular articles